XPS™ contract signed with leading hospital in Boston
The XPS™ is the first sold to New England, USA. Delivery and installation of the XPS™ is estimated to take place early May 2016.
Boston’s Brigham and Women’s Hospital (BWH) is an international leader in many areas of medicine and is a teaching hospital for Harvard Medical School. BWH has a well-developed lung transplant program and with the investment in the Ex Vivo Lung Perfusion (EVLP) technology and the XPS™ BWH will get the opportunity to increase the lung transplant program and support more patients.
XPS™ is the only CE-marked and FDA approved (Humanitarian Device Exemptions approval) integrated system on the market today which gives the user the flexibility to perform evaluation of lungs before transplantation through a standardized and simplified procedure. Use of XPS™ has shown good clinical results at 18 clinics in the US, many of which are national leaders in their field. Six XPS™ contracts have now been signed by European clinics, giving them access to the XPS™ system for lung transplantation, and the company notes continuing high interest for the XPS™ in the US and in Europe.
“We are delighted and proud that EVLP with XPS™ and STEEN Solution™ will be used for evaluating lungs for transplantation at the very well reputed Brigham and Women’s Hospital in Boston. This is one of only two hospitals performing lung transplantation in all of the states in the North-East (New England) of the USA. The company sees a continued high interest from American and European clinics to set up XVIVOs XPS ™ system to facilitate lung evaluation with the aim of using more of the donated lungs”, says Magnus Nilsson, CEO of XVIVO Perfusion.
April 15, 2016
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, email@example.com
Magnus Nilsson, CEO, +46 31 788 2150, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication onApril 15, 2016 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com